UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
|
|
||
|
(Exact name of registrant as specified in its charter) |
||
|
|
|
|
|
(State or other jurisdiction |
(Commission File Number) |
(IRS Employer Identification No.) |
|
of incorporation) |
|
|
|
|
|
|
|
|
|
|
|
(Address of principal executive offices) |
(Zip Code) |
|
|
|
||
|
Registrant’s telephone number, including area code: ( ____________________________________________________________________________ |
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Securities Act:
|
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(b)
On September 28, 2022, Mark C. Wiggins notified TRACON Pharmaceuticals, Inc. (the “Company”) that he was resigning as the Company’s Chief Business Officer, effective September 30, 2022, to pursue other professional opportunities. Mr. Wiggins’ resignation is not a result of any disagreement with the Company, and he has agreed to serve as a consultant to the Company following his resignation.
|
Item 8.01 |
Other Events. |
On September 29, 2022, the International Court of Arbitration of the International Chamber of Commerce (the “ICC”) informed the Company that it extended the time limit for the arbitral tribunal (the “Tribunal”) to render a final decision in the Company’s ongoing binding arbitration with I-Mab Biopharma (“I-Mab”) from September 30, 2022 until November 30, 2022. The arbitration hearing between the Company and I-Mab concluded on February 28, 2022, and the final post-hearing briefs were submitted by the Company and I-Mab to the Tribunal on May 25, 2022.
Forward-Looking Statements
Statements made in this report regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding the timing of the Tribunal’s final decision in the arbitration and any extensions it may request to render a final decision. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: the risk that the timing for a final decision by the Tribunal will be extended and other risks described in the Company’s filings with the Securities and Exchange Commission under the heading “Risk Factors”. All forward‐looking statements contained in this report speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: September 30, 2022 |
|
|
|
TRACON Pharmaceuticals, Inc. |
||
|
|
|
|
|
|||
|
|
|
|
|
By: |
|
/s/ Charles P. Theuer, M.D., Ph.D. |
|
|
Name: |
|
Charles P. Theuer, M.D., Ph.D. |
|||
|
|
|
|
President and Chief Executive Officer
|
|||
Document and Entity Information |
Sep. 28, 2022 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Sep. 28, 2022 |
| Entity Registrant Name | TRACON Pharmaceuticals, Inc |
| Entity Tax Identification Number | 34-2037594 |
| Entity Central Index Key | 0001394319 |
| Entity Emerging Growth Company | false |
| Entity File Number | 001-36818 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 4350 La Jolla Village Drive |
| Entity Address, Address Line Two | Suite 800 |
| Entity Address, City or Town | San Diego |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 92122 |
| City Area Code | 858 |
| Local Phone Number | 550-0780 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.001 per share |
| Trading Symbol | TCON |
| Security Exchange Name | NASDAQ |